Eosinophil ETosis-Mediated Release of Galectin-10 in Eosinophilic Granulomatosis With Polyangiitis.


Journal

Arthritis & rheumatology (Hoboken, N.J.)
ISSN: 2326-5205
Titre abrégé: Arthritis Rheumatol
Pays: United States
ID NLM: 101623795

Informations de publication

Date de publication:
09 2021
Historique:
received: 03 06 2020
accepted: 04 03 2021
pubmed: 23 3 2021
medline: 21 9 2021
entrez: 22 3 2021
Statut: ppublish

Résumé

Eosinophils are tissue-dwelling immune cells. Accumulating evidence indicates that a type of cell death termed ETosis is an important cell fate involved in the pathophysiology of inflammatory diseases. Although the critical role of eosinophils in eosinophilic granulomatosis with polyangiitis (EGPA; formerly Churg-Strauss syndrome) is well established, the presence of eosinophil ETosis (EETosis) is poorly understood. We undertook this study to better understand the characteristics of EETosis. In vitro studies using blood-derived eosinophils were conducted to characterize EETosis. The occurrence of EETosis in tissues from patients with EGPA was studied by immunostaining and electron microscopy. Serum concentrations of eosinophil-derived proteins in healthy controls, patients with asthma, and EGPA patients with active disease or with disease in remission (n = 15 per group) were examined. EETosis was reliant on reactive oxygen species and peptidylarginine deiminase type 4-dependent histone citrullination, resulting in the cytolytic release of net-like eosinophil extracellular traps, free galectin-10, and membrane-bound intact granules. The signature of EETosis, including loss of cytoplasmic galectin-10 and deposition of granules, was observed in eosinophils infiltrating various tissues from EGPA patients. Serum eosinophil granule proteins and galectin-10 levels were increased in EGPA and positively correlated with disease activity as assessed by the Birmingham Vasculitis Activity Score (r = 0.8531, P < 0.0001 for galectin-10). When normalized to blood eosinophil counts, this correlation remained for galectin-10 (r = 0.7168, P < 0.0001) but not for granule proteins. Galectin-10 levels in active EGPA positively correlated with serum interleukin-5 levels. Eosinophils infiltrating diseased tissues in EGPA undergo EETosis. Considering the exclusive expression and large pool of cytoplasmic galectin-10 in eosinophils, elevated serum galectin-10 levels in patients with EGPA might reflect the systemic occurrence of cytolytic EETosis.

Identifiants

pubmed: 33750029
doi: 10.1002/art.41727
pmc: PMC8403105
mid: NIHMS1683091
doi:

Substances chimiques

Galectins 0
Reactive Oxygen Species 0
galectin 10, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1683-1693

Subventions

Organisme : NIAID NIH HHS
ID : R37 AI020241
Pays : United States

Informations de copyright

© 2021, American College of Rheumatology.

Références

J Exp Med. 2010 Aug 30;207(9):1853-62
pubmed: 20733033
Allergol Int. 2019 Oct;68(4):430-436
pubmed: 31266709
Ann N Y Acad Sci. 2007 Jun;1107:392-9
pubmed: 17804567
J Allergy Clin Immunol. 2014 Jun;133(6):1728-34.e1
pubmed: 24439077
J Leukoc Biol. 2018 Jul;104(1):85-93
pubmed: 29749658
Pediatr Int. 1999 Apr;41(2):142-6
pubmed: 10221016
Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18478-83
pubmed: 19017810
Allergol Int. 2018 Jul;67(3):414-416
pubmed: 29242145
Allergy Asthma Proc. 2003 Jul-Aug;24(4):269-74
pubmed: 12974194
Blood. 2013 Mar 14;121(11):2074-83
pubmed: 23303825
Ann N Y Acad Sci. 2005 Jun;1051:121-31
pubmed: 16126951
J Am Acad Dermatol. 2002 Aug;47(2):209-16
pubmed: 12140466
J Allergy Clin Immunol. 2018 Feb;141(2):571-585.e7
pubmed: 28943470
J Exp Med. 2008 Jan 21;205(1):79-90
pubmed: 18195069
BMC Rheumatol. 2019 Mar 8;3:9
pubmed: 30886997
Thorax. 1997 Jun;52(6):569-74
pubmed: 9227728
Intern Emerg Med. 2017 Aug;12(5):577-585
pubmed: 28623488
Arthritis Rheum. 1990 Aug;33(8):1094-100
pubmed: 2202307
Proteomics Clin Appl. 2009;3(10):1151-1173
pubmed: 21048890
J Cell Biol. 2012 Sep 3;198(5):773-83
pubmed: 22945932
Blood. 2018 Nov 15;132(20):2183-2187
pubmed: 30154112
Front Immunol. 2018 Nov 26;9:2763
pubmed: 30534130
Am J Respir Crit Care Med. 2000 Jun;161(6):2074-85
pubmed: 10852790
Annu Rev Pathol. 2020 Jan 24;15:179-209
pubmed: 31977298
Nat Commun. 2014 Aug 13;5:4627
pubmed: 25115909
Science. 2019 May 24;364(6442):
pubmed: 31123109
J Leukoc Biol. 2020 Jul;108(1):139-149
pubmed: 32108369
Front Immunol. 2012 Nov 29;3:360
pubmed: 23264775
Annu Rev Immunol. 2018 Apr 26;36:489-517
pubmed: 29400998
Rheumatol Int. 2021 Feb;41(2):449-454
pubmed: 32770271
Allergol Int. 2020 Apr;69(2):178-186
pubmed: 32139163
Nat Rev Immunol. 2017 Dec;17(12):746-760
pubmed: 28891557
Arthritis Rheum. 2000 Aug;43(8):1897-900
pubmed: 10943883
Neurology. 2020 Apr 21;94(16):e1726-e1737
pubmed: 32217776
Allergol Int. 2021 Jan;70(1):19-29
pubmed: 33189567
J Proteome Res. 2016 May 6;15(5):1524-33
pubmed: 27005946
J Allergy Clin Immunol. 2016 Jan;137(1):258-267
pubmed: 26070883
N Engl J Med. 2017 May 18;376(20):1921-1932
pubmed: 28514601
Clin Exp Rheumatol. 2017 Mar-Apr;35 Suppl 103(1):27-32
pubmed: 28229830
Allergy. 2013 Mar;68(3):274-84
pubmed: 23347072
Nat Protoc. 2014 Oct;9(10):2382-94
pubmed: 25211515
J Allergy Clin Immunol. 2008 Aug;122(2):383-90, 390.e1-4
pubmed: 18455220
Sci Signal. 2008 May 27;1(21):pe25
pubmed: 18506034
Arthritis Rheum. 2013 Jan;65(1):1-11
pubmed: 23045170
Gut. 2013 Oct;62(10):1395-405
pubmed: 22895393
J Leukoc Biol. 2020 Jul;108(1):105-112
pubmed: 32272499
Mol Cell. 2015 Mar 19;57(6):1011-1021
pubmed: 25728769
Blood. 2011 Aug 18;118(7):1952-61
pubmed: 21673343
Curr Allergy Asthma Rep. 2016 Jul;16(8):54
pubmed: 27393701

Auteurs

Mineyo Fukuchi (M)

Akita University, Akita, Japan.

Yosuke Kamide (Y)

Sagamihara National Hospital, Kanagawa, Japan.

Shigeharu Ueki (S)

Akita University, Akita, Japan.

Yui Miyabe (Y)

Akita University, Akita, Japan.

Yasunori Konno (Y)

Akita University, Akita, Japan.

Nobuyuki Oka (N)

Kyoto Konoe Rehabilitation Hospital, Kyoto, Japan.

Hiroki Takeuchi (H)

Kyoto Minami Hospital, Kyoto, Japan.

Souichi Koyota (S)

Akita University, Akita, Japan.

Makoto Hirokawa (M)

Akita University, Akita, Japan.

Takechiyo Yamada (T)

Akita University, Akita, Japan.

Rossana C N Melo (RCN)

Federal University of Juiz de Fora, Juiz de Fora, Brazil, and Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States.

Peter F Weller (PF)

Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States.

Masami Taniguchi (M)

Sagamihara National Hospital, Kanagawa, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH